Clover Health Investments (CLOV) EBITDA (2019 - 2026)

Clover Health Investments' EBITDA history runs 8 years deep, the most recent figure standing at $27.3 million for Q1 2026.

• Quarterly EBITDA rose 2245.53% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.9 million (down 134.05% YoY) and the FY2025 annual result came in at -$85.5 million, down 86.95% from the prior year.
• EBITDA was $27.3 million for Q1 2026 at Clover Health Investments, up from -$49.3 million in the prior quarter.
• Across five years, EBITDA topped out at $27.3 million in Q1 2026 and bottomed at -$102.7 million in Q2 2022.
• A 5-year average of -$35.1 million and a median of -$24.4 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2025 — EBITDA plunged 246.92% — and 2026, when it soared 2245.53%.
• Clover Health Investments' EBITDA stood at -$22.4 million in 2022, then sank by 182.35% to -$63.1 million in 2023, then surged by 66.03% to -$21.4 million in 2024, then sank by 129.95% to -$49.3 million in 2025, then soared by 155.42% to $27.3 million in 2026.
• Business Quant data shows CLOV's EBITDA at $27.3 million in Q1 2026, -$49.3 million in Q4 2025, and -$24.4 million in Q3 2025.